Lifecore Biomedical (LFCR) Projected to Post Earnings on Tuesday

Key Points

• Lifecore Biomedical is expected to report Q3 2026 results on Tuesday, November 3. Analysts forecast a loss of $0.2975 per share and revenue of $25.57 million; the earnings call is scheduled for November 6.
• In its previous quarter, Lifecore reported a $0.19 per-share loss, matching estimates, while revenue of $34.17 million was essentially in line with expectations. Analysts project full-year and next-year losses of $1.02 and $1.08 per share, respectively.
• Analyst sentiment is cautious: four analysts rate the stock Hold and one rates it Sell, producing a consensus “Reduce” rating and a $6.50 price target. Shares recently opened at $6.44, with a 52-week range of $3.63 to $8.98.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) is expected to post its Q3 2026 resultson Tuesday, November 3rd. Analysts expect Lifecore Biomedical to post earnings of ($0.2975) per share and revenue of $25.57 million for the quarter. Individuals can find conference call details on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 6, 2026 at 12:30 PM ET.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($0.19) earnings per share for the quarter, hitting the consensus estimate of ($0.19). The business had revenue of $34.17 million for the quarter, compared to analyst estimates of $34.18 million. On average, analysts expect Lifecore Biomedical to post ($1.02) EPS for the current fiscal year and ($1.08) EPS for the next fiscal year.

Lifecore Biomedical Price Performance

Shares of NASDAQ:LFCR opened at $6.44 on Tuesday. The business's 50 day moving average price is $5.26 and its 200-day moving average price is $5.56. Lifecore Biomedical has a 1 year low of $3.63 and a 1 year high of $8.98. The firm has a market capitalization of $243.75 million, a price-to-earnings ratio of -6.02 and a beta of 0.98.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Zacks Research upgraded shares of Lifecore Biomedical from a "strong sell" rating to a "hold" rating in a research report on Wednesday, July 29th. Craig Hallum lowered shares of Lifecore Biomedical from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 28th. Weiss Ratings raised shares of Lifecore Biomedical from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, October 16th. Barrington Research downgraded shares of Lifecore Biomedical from an "outperform" rating to a "hold" rating in a research report on Tuesday, September 29th. Finally, William Blair downgraded shares of Lifecore Biomedical from an "outperform" rating to a "hold" rating in a research report on Monday, September 28th. Four equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Reduce" and a consensus target price of $6.50.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc is a contract development and manufacturing organization that provides development, formulation, aseptic filling, packaging and other manufacturing services for pharmaceutical and biopharmaceutical companies. The company specializes in complex sterile injectable products and supports customers from development through commercial production.

Lifecore has particular expertise in hyaluronic acid, a naturally occurring substance used in ophthalmic, orthopedic, aesthetic and other medical applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.